Allan K Hansen1, David J Brooks2,3,4, Per Borghammer2. 1. Department of Nuclear Medicine and PET-Centre, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, bld. 10G, DK-8000, Aarhus C, Denmark. ah@clin.au.dk. 2. Department of Nuclear Medicine and PET-Centre, Institute of Clinical Medicine, Aarhus University, Norrebrogade 44, bld. 10G, DK-8000, Aarhus C, Denmark. 3. Division of Neuroscience, Department of Medicine, Imperial College London, London, UK. 4. Division of Neuroscience, Newcastle University, Newcastle, UK.
Abstract
PURPOSE: Recent evidence suggests that the tau radiotracer [18F]THK-5351 displays high affinity for the monoamine oxidase type B (MAO-B) enzyme. Utilizing another tau-tracer, flortaucipir ([18F]AV-1451), we previously reported that non-demented Parkinson's disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake. However, 59 % of these patients were receiving MAO-B inhibitors at the time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding. PROCEDURES: We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson's disease patients who received MAO-B inhibitors with those who did not. RESULTS: Sixteen of 27 Parkinson's disease patients received MAO-B inhibitors at the time of scan. We found no significant flortaucipir uptake differences between the groups at voxel or regional levels. CONCLUSION: Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, MAO-B does not appear to be a significant binding target of flortaucipir.
PURPOSE: Recent evidence suggests that the tau radiotracer [18F]THK-5351 displays high affinity for the monoamine oxidase type B (MAO-B) enzyme. Utilizing another tau-tracer, flortaucipir ([18F]AV-1451), we previously reported that non-demented Parkinson's diseasepatients show off-target binding in subcortical structures, but no appreciable cortical uptake. However, 59 % of these patients were receiving MAO-B inhibitors at the time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding. PROCEDURES: We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson's diseasepatients who received MAO-B inhibitors with those who did not. RESULTS: Sixteen of 27 Parkinson's diseasepatients received MAO-B inhibitors at the time of scan. We found no significant flortaucipir uptake differences between the groups at voxel or regional levels. CONCLUSION: Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, MAO-B does not appear to be a significant binding target of flortaucipir.
Authors: J S Fowler; R R MacGregor; A P Wolf; C D Arnett; S L Dewey; D Schlyer; D Christman; J Logan; M Smith; H Sachs Journal: Science Date: 1987-01-23 Impact factor: 47.728
Authors: Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb Journal: Alzheimers Dement Date: 2013-02-12 Impact factor: 21.566
Authors: Allan K Hansen; Karoline Knudsen; Thea P Lillethorup; Anne M Landau; Peter Parbo; Tatyana Fedorova; Hélène Audrain; Dirk Bender; Karen Østergaard; David J Brooks; Per Borghammer Journal: Brain Date: 2016-05-05 Impact factor: 13.501
Authors: J S Fowler; N D Volkow; J Logan; G J Wang; R R MacGregor; D Schyler; A P Wolf; N Pappas; D Alexoff; C Shea Journal: Synapse Date: 1994-10 Impact factor: 2.562
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Sangram Nag; Patrik Fazio; Lutz Lehmann; Georg Kettschau; Tobias Heinrich; Andrea Thiele; Marie Svedberg; Nahid Amini; Samira Leesch; Ana M Catafau; Jonas Hannestad; Andrea Varrone; Christer Halldin Journal: J Nucl Med Date: 2015-11-19 Impact factor: 10.057
Authors: Michael J Pontecorvo; Michael D Devous; Michael Navitsky; Ming Lu; Stephen Salloway; Frederick W Schaerf; Danna Jennings; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Abhinay D Joshi; Andrew Siderowf; Mark A Mintun Journal: Brain Date: 2017-03-01 Impact factor: 13.501
Authors: Dustin W Wooten; Laura Ortiz-Terán; Nevena Zubcevik; Xiaomeng Zhang; Chuan Huang; Jorge Sepulcre; Nazem Atassi; Keith A Johnson; Ross D Zafonte; Georges El Fakhri Journal: J Neurotrauma Date: 2019-08-01 Impact factor: 5.269
Authors: Belen Pascual; Quentin Funk; Paolo Zanotti-Fregonara; Neha Pal; Elijah Rockers; Meixiang Yu; Bryan Spann; Gustavo C Román; Paul E Schulz; Christof Karmonik; Stanley H Appel; Joseph C Masdeu Journal: J Nucl Med Date: 2019-07-26 Impact factor: 10.057